Progesterone and Estrogen Differentially Regulate DC Functions in Lupus Autoimmun
黄体酮和雌激素差异调节狼疮自身免疫中的 DC 功能
基本信息
- 批准号:7864226
- 负责人:
- 金额:$ 12.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-06-16 至 2013-05-31
- 项目状态:已结题
- 来源:
- 关键词:AfricaAgonistAndrogensAnimal Disease ModelsAnimal ModelAnimalsAntigen-Antibody ComplexAntigensAutoantibodiesAutoimmune DiseasesAutoimmunityB-LymphocytesBackCD4 Positive T LymphocytesCell physiologyCellsDataDefectDendritic CellsDendritic cell activationDevelopmentDiseaseEmployee StrikesEpidemicEpidemiologyEstrogensExhibitsExperimental ArthritisFeedsFemaleFetusGeneticGlomerulonephritisGonadal Steroid HormonesGrantHIVHealthHelper-Inducer T-LymphocyteHomeostasisHormonalHormonesHumanHuman Herpesvirus 2ImmuneImmunityImmunosuppressive AgentsInterferon-alphaInterferonsLupusLymphocyteMediatingMediator of activation proteinMifepristoneModelingMusMyelogenousNatural ImmunityNephritisNuclear AntigensPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhenotypePopulationPredispositionPregnancyPrevalencePreventionProductionProgesteroneProteinuriaRegulationRegulatory T-LymphocyteResearch DesignResearch PersonnelRoleSLEB1 geneSLEB2 geneSLEB3 geneSex CharacteristicsSkinSynthetic ProgestogensSystemic Lupus ErythematosusT-LymphocyteTestingTissuesToll-like receptorsViralVirusWomanWomen&aposs Roleadaptive immunitybasebirth controlcell motilityclinically significantcongeniccytokinedimorphismdisorder preventionhormone regulationhuman TLR7 proteinimmune functionin vivoinhibitor/antagonistinsightlupus prone micelupus-likemicrobialmigrationmortalitynovel therapeutic interventionprogramsreceptorreconstitutionsex
项目摘要
DESCRIPTION (provided by applicant): Dendritic cells (DCs) maintain tolerance by disabling autoreactive T helper cells and generating regulatory T cells. In systemic lupus erythematosus (SLE), tolerance is broken through aberrant activation and homeostasis of DCs. In health, DCs discern self from non-self and infected tissues via toll-like receptors (TLRs). In SLE, however, immune complexes (ICs) comprised of autoantibodies (autoAbs) and nuclear antigens (Ags), through TLRs 7 and 9, activate myeloid DCs (mDCs) and stimulate plasmacytoid DCs (pDCs) to make large amounts of interferon-alpha (IFN-a), which feeds back to enhance activation of mDCs and autoreactive lymphocytes. Female sex steroids are implicated in SLE pathogenesis because 1) nine out of ten patients are female; 2) SLE patients show increased estrogen (E) activity and decreased progesterone (Pg) and androgen activity; 3) in SLE animal models, disease is exacerbated by E; and 4) E has direct stimulatory effects on B cells and DCs. In contrast, Pg is an immunosuppressive female sex steroid. How female sex steroids, particularly Pg, regulate DC functions and lupus autoimmunity is poorly understood. We have shown that Pg suppresses TLR-induced IFN- a production by pDCs in mice, which suggested Pg could regulate lupus disease. Indeed, our new preliminary data show that continuous Pg treatment significantly decreased mortality and nephritis in lupus-prone NZB x NZW F1 (NZB/W) mice. We now hypothesize that Pg and E have opposing effects on lupus disease development through differential regulation of DC functions. To test this, we will compare the effects of E and Pg on DC cytokine production, migration, and T cell stimulation in normal C57BL/6 (B6) mice. To ask whether hormonal regulation of DC functions is operational and normal in lupus mice, we will compare DC functions in B6 mice with those in a model of spontaneous lupus on a B6 background. The B6. Sle1.Sle2.Sle3 triple congenic (B6.TC) model closely reconstitutes the NZB/W phenotype of female-predominant anti-dsDNA Abs, glomerulonephritis and mortality. We will take advantage of this model with genetic studies designed to answer two important questions: 1) are Pg effects on DCs alone sufficient to regulate lupus-like autoimmunity; and 2) does endogenous Pg regulate DCs and disease development? These proposed studies will provide critical insight into hormonal regulation of SLE disease development. Moreover, they will identify novel therapeutic approaches for treatment and prevention of disease development in SLE patients.
描述(由申请人提供):树突状细胞(DC)通过使自身反应性T辅助细胞失活并产生调节性T细胞来维持耐受性。在系统性红斑狼疮(SLE)中,耐受性通过DC的异常激活和稳态被打破。在健康状态下,DC通过Toll样受体(TLR)将自身与非自身和感染组织区分开。然而,在SLE中,由自身抗体(autoAb)和核抗原(Ag)组成的免疫复合物(IC)通过TLR 7和9激活髓样DC(mDC)并刺激浆细胞样DC(pDC)以产生大量干扰素-α(IFN-α),其反馈以增强mDC和自身反应性淋巴细胞的激活。女性性类固醇与SLE发病机制有关,因为1)十分之九的患者是女性; 2)SLE患者显示雌激素(E)活性增加,孕酮(Pg)和雄激素活性降低; 3)在SLE动物模型中,E使疾病恶化;和4)E对B细胞和DC具有直接刺激作用。相反,Pg是一种免疫抑制性雌性类固醇。女性性类固醇,特别是前列腺素,如何调节DC功能和狼疮自身免疫性知之甚少。我们已经证明Pg抑制小鼠中TLR诱导的pDCs产生IFN-α,这表明Pg可以调节狼疮疾病。事实上,我们新的初步数据表明,连续Pg治疗显着降低死亡率和肾炎狼疮倾向NZB x NZW F1(NZB/W)小鼠。我们现在假设Pg和E通过DC功能的差异调节对狼疮疾病的发展具有相反的作用。为了验证这一点,我们将比较E和Pg对正常C57 BL/6(B6)小鼠中DC细胞因子产生、迁移和T细胞刺激的影响。要问是否激素调节的DC功能是可操作的和正常的狼疮小鼠,我们将比较DC功能在B6小鼠与自发性狼疮模型的B6背景。B6。Sle1.Sle2.Sle3三重同源(B6.TC)模型紧密地重建了女性占优势的抗dsDNA抗体、肾小球肾炎和死亡率的NZB/W表型。我们将利用这一模型的遗传学研究,旨在回答两个重要的问题:1)Pg对DC的作用是否足以调节狼疮样自身免疫; 2)内源性Pg是否调节DC和疾病的发展?这些拟议的研究将提供关键的洞察激素调节SLE疾病的发展。此外,他们将确定新的治疗方法,用于治疗和预防SLE患者的疾病发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Grant Hughes其他文献
Grant Hughes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Grant Hughes', 18)}}的其他基金
Regulation of CD4+ T cell responses by a progesterone receptor
黄体酮受体调节 CD4 T 细胞反应
- 批准号:
8510078 - 财政年份:2013
- 资助金额:
$ 12.2万 - 项目类别:
Progesterone and Estrogen Differentially Regulate DC Functions in Lupus Autoimmun
黄体酮和雌激素差异调节狼疮自身免疫中的 DC 功能
- 批准号:
8119292 - 财政年份:2010
- 资助金额:
$ 12.2万 - 项目类别:
Progesterone and Estrogen Differentially Regulate DC Functions in Lupus Autoimmun
黄体酮和雌激素差异调节狼疮自身免疫中的 DC 功能
- 批准号:
7919720 - 财政年份:2009
- 资助金额:
$ 12.2万 - 项目类别:
Progesterone & Estrogen Differentially Regulate DC Function in Lupus Autoimmunity
黄体酮
- 批准号:
8076283 - 财政年份:2008
- 资助金额:
$ 12.2万 - 项目类别:
Progesterone and Estrogen Differentially Regulate DC Functions in Lupus Autoimmun
黄体酮和雌激素差异调节狼疮自身免疫中的 DC 功能
- 批准号:
7532363 - 财政年份:2008
- 资助金额:
$ 12.2万 - 项目类别:
Progesterone and Estrogen Differentially Regulate DC Functions in Lupus Autoimmun
黄体酮和雌激素差异调节狼疮自身免疫中的 DC 功能
- 批准号:
7638015 - 财政年份:2008
- 资助金额:
$ 12.2万 - 项目类别:
Progesterone & Estrogen Differentially Regulate DC Function in Lupus Autoimmunity
黄体酮
- 批准号:
8309418 - 财政年份:2008
- 资助金额:
$ 12.2万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 12.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 12.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 12.2万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 12.2万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 12.2万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 12.2万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 12.2万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 12.2万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 12.2万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 12.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




